All in on AA: Q32 Bio Inc. Restructures to Focus on Bempikibart in AA
Q32 Bio Inc. is restructuring to focus on the advancement of its bempikibart clinical development program for the treatment of patients with alopecia areata (AA). “We have conviction that bempikibart is differentiated from existing AA therapies and has the potential to transform the treatment paradigm for this disease. This is based on the continued emergence […]